KN046 + paclitaxel + carboplatin

KN046 + paclitaxel + carboplatin is a combination regimen used in oncology clinical trials, particularly for advanced and metastatic non-small cell lung cancer (NSCLC). KN046 is a novel bispecific antibody that targets both programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), acting as an immune checkpoint inhibitor to boost T cell-mediated tumor killing. Paclitaxel and carboplatin are well-established cytotoxic chemotherapies that inhibit cancer cell division via disruption of microtubule dynamics and DNA crosslinking, respectively. The combination leverages immunotherapy (KN046) with chemotherapy (paclitaxel and carboplatin) to enhance tumor control and patient outcomes. In a Phase 2 trial, this regimen showed promising efficacy and tolerability as a first-line treatment for metastatic NSCLC, with a high objective response rate and manageable toxicity profile[2].